Omega Therapeutics is halting work on its only clinical-stage candidate as part of a strategic refocus centered on three ...

Novo Nordisk (NVO) reportedly plans to phase out production of human insulin pens while it ramps up production of other ...

Novo Nordisk is gradually ending production of human insulin pens, the drugmaker told Reuters, as it spends billions to ramp ...

The head of the company that makes the diabetes and obesity drugs Ozempic and Wegovy has warned that compounded versions of the active ingredient in those medications have now been linked to at least ...

EU antitrust regulators have asked pharma rivals and customers for feedback in four business areas in light of Novo Holdings' ...

After rising in premarket trading, Novo Nordisk's U.S.-listed shares fell after the market opened Wednesday as its ...

(CNN) — Compounded versions of semaglutide, the active ingredient in approved diabetes and obesity drugs Ozempic and Wegovy, ...

Novo Nordisk has asked the Food and Drug Administration to bar compounding pharmacies from making copies of its blockbuster weight loss drug semaglutide, arguing that the medication is too complex ...

The global diabetes and obesity epidemic is driving another expansion of Novo Nordisk’s drug-manufacturing operations at its 264-acre campus in Clayton. The company will begin a $65 million expansion ...

Novo Nordisk Fonden tjener ikke kun milliarder på vægttabs- og diabetesmedicin ved at eje Novo Nordisk. Fonden ejer også en af verdens største leverandører af ingredienser til den globale ...

The Danish drug company Novo Nordisk has been sanctioned by the UK pharmaceutical industry regulator over the way it has promoted its weight loss medications semaglutide (Ozempic/Wegovy) and ...